Scholtz & Company, LLC Intellia Therapeutics, Inc. Transaction History

Scholtz & Company, LLC

  • $234 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022
SELL
$100.76 - $138.36 $220,160 - $302,316
-2,185 Closed
0 $0
Q3 2021

Nov 15, 2021
SELL
$132.37 - $176.78 $100,601 - $134,352
-760 Reduced 25.81%
2,185 $293,000
Q2 2021

Aug 09, 2021
BUY
$60.88 - $161.91 $179,291 - $476,824
2,945 New
2,945 $477,000

Others Institutions Holding NTLA

# of Institutions
320
Shares Held
88.6M
Call Options Held
673K
Put Options Held
865K
View Full List

About Intellia Therapeutics, Inc.

NTLA Quotes by TradingView
  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.08B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Scholtz & Company, LLC Portfolio

Follow Scholtz & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Scholtz & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Scholtz & Company, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email